Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RegenXBio ( (RGNX) ) just unveiled an update.
On March 18, 2026, REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve a dispute over the amount of sublicense fees previously paid under a 2009 license arrangement. REGENXBIO agreed to pay $10 million to GSK within three business days of the agreement’s effective date to address alleged underpayment of sublicense fees on amounts received from sublicensees, including royalties.
The settlement provides mutual releases of all past claims and certain specified future claims related to the license, reducing legal uncertainty around a key revenue-sharing arrangement. REGENXBIO will continue to remit to GSK amounts received from existing sublicensees using its current allocation methodology, suggesting operational continuity for its licensing business despite the one-time financial outlay.
The most recent analyst rating on (RGNX) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.
Spark’s Take on RGNX Stock
According to Spark, TipRanks’ AI Analyst, RGNX is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses and continued cash burn) and bearish technical positioning (below key moving averages with negative MACD). Offsetting factors include constructive earnings-call catalysts and liquidity guidance into early 2027 (with a potential AbbVie milestone), but regulatory setbacks and program risk remain material.
To see Spark’s full report on RGNX stock, click here.
More about RegenXBio
REGENXBIO Inc. is a biotechnology company focused on developing gene therapy treatments based on its proprietary NAV Technology Platform. The company generates revenue through licensing and sublicensing its gene therapy technology to biopharmaceutical partners and receives associated fees and royalties tied to these sublicense agreements.
Average Trading Volume: 960,869
Technical Sentiment Signal: Sell
Current Market Cap: $431.5M
See more data about RGNX stock on TipRanks’ Stock Analysis page.